Non-Proliferation of MCF7 breast adenocarcinoma cells post-treatment with novel bacterium fermented metabolites

Introduction: Cancers are increasingly becoming an economic burden on health care systems, especially of developing economies. High medical cost has resulted in a dependence on herbal and complimentary therapies. Here we investigated the effects of an extract containing lactones obtained from the recently identified Bacillus mojavensis strain nov. C14135 on MCF7 breast cancer cells. Materials/Methods: MCF7 breast adenocarcinoma cells cultured in RPMI 1640 HyQ® media supplemented with 10%FBS, Penn/Strep and Amphotericin B. Flasks incubated at 37oC, 5% CO2 and controlled RH. Cells grown to approx. 95% confluence, then treated with 200µl of .22µm-filtered extract. Control flasks remained untreated. Incubated flasks were checked at 12hr, 24hr and 48hr interval. Results: Microscopic analysis of cells revealed extensive cellular damage. Dye exclusion analysis employing Trypan blue revealed significant cell mortality resulting in a reduction in cell numbers. We employed Mitochondria Dehydrogenase (MDS) assay and Annexin-FITC-V Apoptosis analysis, which confirmed prior results. Conclusion: We report what appears to be possibly cellular shrinking and aggregation, followed by detachment from the substrate and eventual cellular destruction. The results appear to demonstrate that compounds within this fermented fraction are potentially catatonic to these breast cancer cells. This bioactivity of the extract appears to be unique and is possibly a result of innate compounds including Pyrrolo [1, 2-a] piperazine-3, 6-dione, identified following GC/MS fragmentation. Further experiments will ensue to identify, isolate and demonstrate the involvement and potential activity of the identified compounds. Analysis will include comparing results against currently used antineoplastic agents.